Clinical Trial Details
| Trial ID: | L3275 |
| Source ID: | NCT02672839 |
| Associated Drug: | Lgd-6972 Solution |
| Title: | A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Type 2 Diabetes Mellitus (T2DM) |
| Interventions: | DRUG: LGD-6972 Solution|DRUG: LGD-6972 Capsules |
| Outcome Measures: | Primary: Pharmacokinetics Analysis- Area Under the Concentration Curve (AUC), AUC: ratio: medium test form to reference form, Pre-dose, 1,2,4,6,8,10,12,16,24,36,48,72 hrs, 7 and 14 days post dose|Pharmacokinetics Analysis- Maximum Concentration (Cmax), Cmax: ratio: medium test form to reference form, Pre-dose, 1,2,4,6,8,10,12,16,24,36,48,72 hrs, 7 and 14 days post dose | Secondary: Severity of all Adverse Events graded according to the Common Terminology Criteria for Adverse Events (CTCAE), The severity of all adverse events will be graded according to the CTCAE version 4.0 from dosing until 14 days post-dose, Day -1, 24, 48, 72hrs, and 7day and 14day post dose |
| Sponsor/Collaborators: | Sponsor: Ligand Pharmaceuticals | Collaborators: Medpace, Inc. |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE1 |
| Enrollment: | 12 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2016-02 |
| Completion Date: | 2016-05 |
| Results First Posted: | |
| Last Update Posted: | 2016-05-18 |
| Locations: | Medpace, Inc, Cincinnati, Ohio, 45227, United States |
| URL: | https://clinicaltrials.gov/show/NCT02672839 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|